ClinicalTrials.gg
RecruitingNCT03862781RICARTUpdated Jul 20, 2026

Intra-Corporeal Anastomosis Result in Quicker Return of Bowel Function/Earlier Discharge

An interventional study of Right Hemicolectomy in Colorectal Disorders, sponsored by Corewell Health West. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Corewell Health West · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jan 2019; still recruiting 7 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Adult patients who are regularly scheduled to undergo a right hemicolectomy via a minimally invasive approach (robotic or laparoscopic) with the creation of an anastomosis.

Read the detailed description

The purpose of this trial is to investigate whether minimally invasive right colectomies done with an intra-corporeal anastomosis result in quicker return of bowel function and earlier discharge. The primary endpoint of this study will be return of bowel function as measured by passage of flatus and bowel motions. The secondary endpoints will be inpatient length of stay, incision length, postoperative narcotic use, surgical site infection (superficial, deep and organ-space), perioperative morbidity and operating room charges.

02

Conditions studied

  • Colorectal Disorders
03

In context

Lead sponsor

Corewell Health West is the lead sponsor of 16 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible patients are those over 18 years of age who are regularly scheduled to undergo a right hemicolectomy via a minimally invasive approach (robotic or laparoscopic) with the creation of an anastomosis. Right colectomy will be defined as removal of the ascending colon, ligation of the ileocolic artery and vein, +/- removal of the terminal ileum, +/- removal of the proximal transverse colon, and +/- removal of the right branch of the middle colic artery and vein.

Exclusion criteria

Exclusion Criteria:

  • Pregnant women
  • Additional colon resection is planned (i.e. left colectomy or proctectomy)
  • Vulnerable populations such as prisoners or adults unable to give consent
  • If the scheduled surgery is planned at Butterworth hospital (as to standardize the nursing care received postoperatively)
  • Emergent cases

Patients will be excluded from the study intra-operatively if:

  • The procedure is converted to an open resection
  • If a loop ileostomy is performed in addition to the right colectomy
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
125 participants (estimated)

Study arms

  • Other
    Intra-corporeal

    Right Hemicolectomy

    Procedure: Right Hemicolectomy

  • Other
    Extra-corporeal

    Right Hemicolectomy

    Procedure: Right Hemicolectomy

Interventions

  • ProcedureRight Hemicolectomy

    Minimally invasive approach (robotic or laparoscopic) with the creation of an anastomosis.

06

What researchers measure

Primary outcomes

  1. Return of bowel function

    Flatus and bowel motions

    Time frame: up to 2 weeks

Secondary outcomes

  1. Inpatient length of stay

    Days in the hospital after surgery

    Time frame: up to 2 weeks

  2. Incision length

    cm's

    Time frame: Surgery date

  3. Postoperative narcotic use

    Average pain scores over first 5 hospital days

    Time frame: up to 2 weeks

  4. Surgical site infection

    (superficial, deep and organ-space)

    Time frame: up to 6 weeks

  5. Perioperative morbidity

    Disease state

    Time frame: Baseline (Prior to surgery)

  6. Operating room charges

    Fees for operating room

    Time frame: Surgery date

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — There is no plan to Share IPD.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2019 (actual). Primary completion is estimated for Dec 2026, 95 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2019
First posted
Mar 5, 2019
StartActual
Jan 28, 2019
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03862781
Lead sponsor
Corewell Health West
Responsible party
James W. Ogilvie (Colorectal Surgeon, Corewell Health West) — Principal investigator
First posted
Mar 5, 2019
Start date
Jan 28, 2019
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 20, 2026

Study contacts

kendra Selby
Contact
kendra.selby@helendevoschidrens.org
616-486-0281
James W Ogilvie, Jr., MS
principal investigator · Corewell Health West

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion